• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Glaukos Corp (NY: GKOS )

    96.82 -0.38 (-0.39%)
    Streaming Delayed Price Updated: 2:52 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 168,009
    Open 96.78
    Bid (Size) 96.73 (3)
    Ask (Size) 96.91 (2)
    Prev. Close 97.20
    Today's Range 96.29 - 97.48
    52wk Range 45.38 - 103.66
    Shares Outstanding 49,470,423
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Glaukos Announces the Release of its 2023 Sustainability Report
    From Glaukos Corporation
    Via Business Wire
    Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
    From Glaukos Corporation
    Via Business Wire

    Performance

    YTD
    +25.61%
    +25.61%
    1 Month
    +4.00%
    +4.00%
    3 Month
    +2.81%
    +2.81%
    6 Month
    +44.90%
    +44.90%
    1 Year
    +104.26%
    +104.26%

    More News

    Read More
    Analyst Ratings For Glaukos
    Via Benzinga
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    5 Analysts Have This To Say About Glaukos
    Via Benzinga
    Glaukos: Q4 Earnings Insights
    Via Benzinga
    Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
    From Glaukos Corporation
    Via Business Wire
    Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
    From Glaukos Corporation
    Via Business Wire
    Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Earnings Scheduled For February 21, 2024
    Via Benzinga
    Analyst Ratings For Glaukos
    Via Benzinga
    Unveiling 7 Analyst Insights On Glaukos
    Via Benzinga
    Analyst Ratings for Glaukos
    Via Benzinga
    Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
    From Glaukos Corporation
    Via Business Wire
    Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
    From Glaukos Corporation
    Via Business Wire
    Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
    From Glaukos Corporation
    Via Business Wire
    Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
    Via Benzinga
    4 Analysts Have This to Say About Glaukos
    Via Benzinga
    Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
    From Glaukos Corporation
    Via Business Wire
    iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
    Via Benzinga
    Exposures Product Safety
    Dow Extends Rally As Treasury Yields Tank
    Via Talk Markets
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
    Via Benzinga
    Exposures Product Safety
    Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
    From Glaukos Corporation
    Via Business Wire
    Glaukos Announces Participation in Stifel Healthcare Conference
    From Glaukos Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.